The results of the ICON6 trial were presented in abstract form at the recent NCRI Cancer Conference in Liverpool, UK. The phase III trial randomly assigned 456 women with relapsed, platinum-sensitive ovarian cancer after platinum chemotherapy to receive placebo (group 1), the VEGFR inhibitor cediranib during chemotherapy then placebo (group 2) or cediranib followed by maintenance with cediranib (group 3). The progression-free survival was 9.4 months in group 1, 11.4 months in group 2 and 12.6 months in group 3 (all significant). Common adverse effects in cediranib-treated women included hypertension and diarrhoea.